Over the last decade or so, a number of articles have been published concerning the link between the use of the atypical antipsychotic drug Risperdal (risperidone) and elevated prolactin levels, ensuing gynecomastia.  (Prolactin is the hormone responsible for breast development and milk production.)

Here, we will discuss one such article, published in a 1999 edition of Journal of Clinical Psychopharmacology.  Titled “Prolactin levels and adverse events in patients treated with risperidone.”, this study by DL Kleinberg et al. reviewed two large then-recent studies that included 841 and 1,884 patients each.  These studies compared patient blood prolactin levels with the occurrence of “six adverse events possibly associated with increased prolactin levels”: “amenorrhea, galactorrhea, and decreased libido in women; erectile dysfunction, ejaculatory dysfunction, gynecomastia, and decreased libido in men”.

With statistical analysis, the study team found “Both risperidone and haloperidol produced dose-related increases in plasma prolactin levels in men and women.”  Further, it was determined that “Among men, the incidence of adverse events was positively correlated with risperidone dose”.

Due to the fact that Janssen Pharmaceuticals, Inc. (the manufacturer of Risperdal) has failed time and again to adequately warn male users of the risk for gynecomastia associated with Risperdal, many affected users have chosen to file Risperdal lawsuits with great success.  If you or a loved one used Risperdal and suffered male breast growth as a result, you too may be entitled to significant financial compensation.  For a free, no-obligation case consultation, contact our team of Risperdal lawyers at the information provided below.  We have the compassion, resources, and skills required to win the compensation you deserve.

(855) 452 – 5529

justinian@dangerousdrugs.us

Our Risperdal Lawsuit Information page is a great place to start if you have any questions about Risperdal.